Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis

Breast Cancer Res Treat. 2008 Feb;107(3):459-60. doi: 10.1007/s10549-007-9564-1. Epub 2007 Apr 24.

Abstract

Encouraged by recent studies on the MTHFR 677C>T polymorphism and breast cancer risk that suggested an association of the 677 TT genotype with increased breast cancer susceptibility in premenopausal women, we performed an analysis of the relationship between breast cancer risk and the MTHFR 677C>T polymorphism in 210 premenopausal breast cancer patients and sex- and agematched healthy control subjects. Our data show a trend for a higher MTHFR 677T allele frequency in breast cancer cases (61.9%) than in controls (51.5%, P = 0.082) supporting the results of previous studies.

Publication types

  • Comment
  • Letter

MeSH terms

  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Female
  • Humans
  • Meta-Analysis as Topic
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Polymorphism, Genetic*

Substances

  • Methylenetetrahydrofolate Reductase (NADPH2)